Pubblicazioni

Autori:

Fedele, Luigi; S., Bianchi; Raffaelli, Ricciarda; Zanconato, Giovanni

Titolo:

A randomized study of the effects of tibolone and transdemal estrogen replacement therapy in postmenopausal women with uterine myomas

Anno:

2000

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

European Journal of Obstetrics Gynecology and Reproductive Biology

ISSN Rivista:

0301-2115

N° Volume:

88

Numero o Fascicolo:

1

Intervallo pagine:

91-94

Parole chiave:

menopause; uterine myomas; tibolone; hormone replacement therapy

Breve descrizione dei contenuti:

Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus aand myomas

Note:

OBJECTIVE: To evaluate the effects of two types of hormone replacement therapy, an estrogen-progestin combination and tibolone, on uterine myomas in menopausal women. STUDY DESIGN: Thirty-eight menopausal women with one or more uterine myomas were randomized to treatment with a transdermal system continuously releasing estradiol 50 microg/day combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month or tibolone tablets 2.5 mg/day. The scheduled duration of both treatments was 12 months. Physical examination and abdominal/transvaginal ultrasonography were performed before entering the study and at 3, 6 and 12 months of treatment. At each ultrasonography the overall uterine volume was determined as well as the size of each myoma and the endometrial thickness and characteristics. RESULTS: No statistically significant difference was detected between the two groups at any time during treatment. However, within-group analysis showed a significant increase of uterine volume and of myoma number and size in the estrogen-progestin group, whereas no such increase occurred in the patients treated with tibolone. Also, the mean endometrium width increased significantly from baseline to the end of treatment in the estrogen-progestin group, but not in the tibolone group. CONCLUSIONS: Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas.

Id prodotto:

7444

Handle IRIS:

11562/7444

depositato il:

14 maggio 2008

ultima modifica:

13 novembre 2022

Citazione bibliografica:

Fedele, Luigi; S., Bianchi; Raffaelli, Ricciarda; Zanconato, Giovanni, A randomized study of the effects of tibolone and transdemal estrogen replacement therapy in postmenopausal women with uterine myomas «European Journal of Obstetrics Gynecology and Reproductive Biology» , vol. 88 , n. 1 , 2000 , pp. 91-94

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo